Search

Summary: A nitrogen‐doped carbon coated subglobose Na3V2(PO4)2F3@C (NVPF) cathode for sodium‐ion batteries was synthesized by using hexadecyl trimethyl ammonium bromide (CTAB) as soft template and polyvinylidene fluoride (PVDF) as carbon source. CTAB plays a significant role on the formation of sphere micelles. Precursor ions are self‐assembled on the surface at appropriate concentration and its mechanism is investigated in subglobose NVPF@C‐4. CTAB also increases the conductivity of carbon layer as −(CH3)3N+ in CTAB is combined with residual carbon from PVDF to form partially N‐doped carbon. Meanwhile, the carbon source PVDF contributes to prevent the generation of impurity Na3V2(PO4)3 by compensating the evaporative fluorine. Generally, CTAB and PVDF play multifunctional roles in regulating Na3V2(PO4)2F3@C cathode with well‐developed crystallite, high rate performance, good conductivity, and ultra‐long cycle life. The specific capacity of NVPF@C‐4 cathode at 0.1 C and 10 C is as high as 121.5 mAh·g−1 and 99.2 mAh·g−1 with high capacity retention of 90.1% even after 1000 cycles at 10 C. The excellent rate performance is also attributed to the high diffusion coefficient of Na+ and high exchange current according to the kinetic analysis. The enhanced electrochemical performances reveal the special regulation in this paper is feasible to obtain excellent structural stability of NVPF materials. [ABSTRACT FROM AUTHOR]

Abstract: Current prognostic signatures need to be improved in identifying high‐risk patients of gastric cancer (GC). Thus, we aimed to develop a reliable prognostic signature that could assess the prognosis risk in GC patients. Two microarray datasets of GSE662254 (n = 300, training set) and GSE15459 (n = 192, test set) were included into analysis. Prognostic genes were screened to construct prognosis‐related gene pairs (PRGPs). Then, a penalized Cox proportional hazards regression model identified seven PRGPs, which constructed a prognostic signature and divided patients into high‐ and low‐risk groups according to the signature score. High‐risk patients showed a poorer prognosis than low‐risk patients in both the training set (hazard ratios [HR]: 6.086, 95% confidence interval [CI]: 4.341–8.533) and test set (1.773 [1.107–2.840]). The PRGPs signature also achieved a higher predictive accuracy (concordance index [C‐index]: 0.872, 95% CI: 0.846–0.897) than two existing molecular signatures (0.706 [0.667–0.744] for a 11‐gene signature and 0.684 [0.642–0.726] for a 24‐lncRNA signature) and TNM stage (0.764 [0.715–0.814]). In conclusion, our study identified a novel gene pairs signature in the prognosis of GC. [ABSTRACT FROM AUTHOR]

5,7-dihydroxy-3',4',6-trimethoxyflavone, commonly known as eupatilin, is a traditional Asian medicinal plant, which is mainly used for the treatment of gastritis, as well as its use as an anti-inflammatory agent. Eupatilin is a bioactive compound; however, its effects on osteosarcoma (OS) have remained to be elucidated. Therefore, the present study aimed to investigate the effects of eupatilin on this malignant bone tumor, using the U-2 OS cell line. The experimental results revealed t hat eupatilin i nhibited U -2 OS cell growth in a concentration-dependent manner and induced G2/M phase cell cycle arrest and apoptosis. Additionally, western blot analysis indicated that eupatilin was able to trigger the mitochondrial apoptotic pathway, demonstrated by the enhanced Bax/B cell lymphoma-2 ratio, decrease in mitochondrial membrane potential, release of cytochrome c, caspase-3 and -9 activation and poly(ADP-ribose)polymerase cleavage detected in the U-2 OS cells. These results indicated that eupatilin was able to inhibit U-2 OS cancer cell proliferation by the induction of apoptosis via the mitochondrial intrinsic pathway. Eupatilin may therefore represent a novel anticancer drug for use in the treatment of osteosarcoma. [ABSTRACT FROM AUTHOR]